According to a No Camels News Flash, Foamix Pharmaceuticals received approval for its product that treats Rosacea, FMX 103 for Rosacea. In a deal with Bayer, Foamix may receive $10 million US Dollars.
Hilltop News
Oppenheimer Equity Research Quarterly Update August 21, 2016
Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea
Sacks: Foamix Starts Patient Enrollment in Phase II Study on FMX103
Foamix Pharmaceuticals Ltd., NY Times
Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea (EMIRA)
Foamix’s FMX103 meets efficacy endpoints in phase 2 trial for papulopustular rosacea
Foamix shares bubble up on Phase 2 data
September 10, 2016 Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea
September 12, 2016
“We are extremely encouraged that our Phase 2 dose-finding study demonstrated that FMX103 appears to be safe and effective in the treatment of moderate-to-severe papulopustular rosacea,” said Dov Tamarkin, Ph.D., CEO of Foamix. “We believe the positive data from our clinical trial could support advancement into Phase 3, and look forward to reviewing these results with the FDA. Our goal is to bring innovative therapies to market in order to address the unmet needs of patients suffering from various dermatological conditions. Based on our current results, FMX103 has the potential to provide significant benefits to the millions of patients who currently struggle with the physical effects of rosacea and the quality of life impact inherent with this disease.” Drug Discovery
“We believe the positive data from our clinical trial could support advancement into phase 3, and look forward to reviewing these results with the FDA,” Dov Tamarkin, PhD, CEO of Foamix, stated in the release
FMX103 meets efficacy endpoints in treating papulopustular rosacea
October 20, 2015 http://www.benzinga.com/news/15/10/5927077/foamix-announces-enrollment-of-first-patient-in-phase-2-clinical-trial-of-fmx103-
December 1, 2016 Foamix to Host Key Opinion Leader Luncheon for Investors Focused on Dermatology, With a Focus on Acne and Rosacea
Meeting and Live Webcast on Friday, December 2, at 12 pm Eastern Time
Keynote presentations by Guy Webster, MD, PhD and Linda Stein Gold, MD (RRDi MAC Member)
Overview of FMX101, a novel minocycline foam for the treatment of moderate-to-severe acne, and FMX103 for the treatment of moderate-to-severe rosacea.